Abstract
Even the most powerful handheld screening tool for glaucoma will not find cases cost-effectively because the disease prevalence is low. However, a tier 1 biomarker tool that enhances disease prevalence followed by the use of a screening tool could serve as a future glaucoma screening strategy.
| Original language | English |
|---|---|
| Pages (from-to) | S13-S14 |
| Journal | Journal of Glaucoma |
| Volume | 33 |
| DOIs | |
| State | Published - 1 Aug 2024 |
Keywords
- Moore’s Law
- glaucoma screening
- technology